Fig. 2From: Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patientsMelanoma-specific antibody responses and overall survival in cohort 2. a, b: Anti-NY-ESO-1, c, d: anti-MelanA/MART1, e, f: anti-TRP1/TYRP1, g, h: anti-TRP2/TYRP2, i, j: anti-gp100. a, c, e, g, i: Differences between responders (R) and non-responders (NR) were tested with Wilcoxon rank-sum tests. Bars represent means and 95% CI, and circles show data from individual patients. b, d, f, h, j: Kaplan-Meier curves showing overall survival (OS) of patients with high vs. low antibody levels at therapy start. Grouping criteria (cutpoints) are given in graphs. Hazard ratios (HR) for high vs. low antibody levels are provided with p-values from log-rank testsBack to article page